Exelixis (NasdaqGS:EXEL) recently announced positive topline results from the STELLAR-303 Phase 3 trial, highlighting the ...

EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of ...

The long term target area is 78.6% of the same move at 1006.00 and the 1000.00 major Gann square. Another level of support is 61.8% at 1022.00. The setback from the 1071.00 (78.6%) swing point took it ...